Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 3/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31048794 | 0.94 | JAK1 (0.36) | JAK1JAK2TYK2JAK3GPR119 | |
| SCHEMBL31049165 | 0.88 | JAK1 (0.47) | JAK1JAK2TYK2JAK3GPR119 | |
| SCHEMBL31048931 | 0.86 | JAK1 (0.40) | JAK1JAK2TYK2JAK3GPR119 | |
| SCHEMBL31048881 | 0.83 | PSEN1 (0.36) | JAK1GPR119RET | |
| SCHEMBL31049053 | 0.81 | JAK1 (0.47) | JAK1JAK2TYK2JAK3GPR119 | |
| SCHEMBL31048788 | 0.81 | JAK1 (0.34) | JAK1JAK2TYK2JAK3GPR119 | |
| SCHEMBL31049031 | 0.78 | JAK1 (0.47) | JAK1JAK2TYK2JAK3GPR119 | |
| SCHEMBL31049065 | 0.78 | JAK1 (0.42) | JAK1JAK2TYK2JAK3GPR119 | |
| SCHEMBL31048890 | 0.77 | JAK1 (0.46) | JAK1JAK2TYK2JAK3GPR119 | |
| SCHEMBL31048863 | 0.77 | PSEN1 (0.36) | GPR119RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024167922-A2 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-08-15 | — | — | WO | disclosed |